Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.37 |
| ▸ | BHMT | Q93088 | 9/20 | 0.36 |
| ▸ | BHMT2 | Q9H2M3 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 2/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | MARS1 | P56192 | 5/20 | 0.32 |
| ▸ | METAP2 | P50579 | 1/20 | 0.32 |
| ▸ | METAP1 | P53582 | 1/20 | 0.32 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2319973 | 0.89 | METAP2 (0.36) | RNPEPBHMTBHMT2MARS1METAP2 | |
| Leucine SCHEMBL15323685 | 0.85 | SLC7A5 (0.47) | RNPEPBHMTBHMT2NOS2NOS3 | |
| Serine SCHEMBL8696833 | 0.84 | BHMT (0.40) | RNPEPBHMTBHMT2NOS2NOS3 | |
| Serine SCHEMBL3883233 | 0.84 | BHMT (0.40) | RNPEPBHMTBHMT2NOS2NOS3 | |
| Threonine SCHEMBL6367180 | 0.83 | METAP2 (0.35) | RNPEPBHMTBHMT2MARS1METAP2 | |
| Serine SCHEMBL3442575 | 0.83 | GSR (0.50) | RNPEPBHMTBHMT2NOS2NOS3 | |
| Sulfuric Acid SCHEMBL1764302 | 0.82 | MARS1 (0.33) | RNPEPMARS1METAP2METAP1 | |
| SCHEMBL2876009 | 0.82 | BHMT (0.41) | RNPEPBHMTBHMT2NOS2NOS3 | |
| Methionine SCHEMBL2022415 | 0.82 | BHMT (0.46) | RNPEPBHMTBHMT2NOS2NOS3 | |
| SCHEMBL7263576 | 0.81 | RNPEP (0.37) | RNPEPBHMTBHMT2MARS1METAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032403-A1 | Crystal structure of the ITK kinase domain | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-02-08 | — | — | US | disclosed |
| WO-2005066335-A1 | CRYSTAL STRUCTURE OF THE INTERLEUKIN-2-INDUCIBLE CELL KINASE (ITK) KINASE DOMAIN | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032403-A1 | Crystal structure of the ITK kinase domain | ITK, DTYMK, WEE1 | RNPEP 1197/4885BHMT 2689/4885BHMT2 3303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.